MAP2K7 and Miyoshi myopathy: Collectively, together with the data in primary MM cells (Figures 6A–6D; Figures S6A and S6B), these results underscore the potency, safety, and cancer cell specificity of the pharmacological approach targeting the GADD45β/MKK7 complex in MM and identify DTP3 as a therapeutic selectively inhibiting the NF-κB survival pathway in cancer (Figure 8).